Clicky

AbbVie Inc.(ABBV)

Description: AbbVie Inc., a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. Its product portfolio includes a range of adult and pediatric pharmaceuticals, including HUMIRA, a biologic therapy administered as a subcutaneous injection to treat various autoimmune diseases; Synthroid used in the treatment of hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated as an adjunct to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, as well as to increase HDL cholesterol levels; Synagis, which protects at-risk infants from severe respiratory disease or respiratory syncytial virus; Sevoflurane, an anesthesia product for human use; Duodopa, a levodopa-carbidopa intestinal gel used to treat advanced Parkinson's disease; and Zemplar used for the prevention and treatment of secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. The company has collaboration with Alvine Pharmaceuticals, Inc. to develop a oral treatment for patients with celiac disease. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois. As of January 01, 2013.AbbVie Inc. operates independently of Abbott Laboratories.


Keywords: S&P 500 Pharmaceutical Products Organic Compounds Chemical Compounds Autoimmune Disease Prostate Cancer Acid Cardiology Respiratory Diseases Distribution Center Thyroid Anesthesia Chloroarenes Gabaa Receptor Positive Allosteric Modulators Cholesterol Testosterone Lipoprotein Hypothyroidism Hyperparathyroidism Secondary Hyperparathyroidism Celiac Disease Advanced Prostate Cancer Exocrine Pancreatic Insufficiency Low Density Lipoprotein Testosterone Replacement Therapy Carbidopa Niacin Triglyceride High Density Lipoprotein Anesthesia Product Benzophenones Celiac Fenofibrate Lupron Research Based Biopharmaceutical

Home Page: www.abbvie.com

ABBV Technical Analysis

1 North Waukegan Road
North Chicago, IL 60064-6400
United States
Phone: 847 932 7900


Officers

Name Title
Mr. Richard A. Gonzalez Chairman & CEO
Mr. Robert A. Michael Vice Chairman & Pres
Ms. Laura J. Schumacher Vice Chairman of External Affairs & Chief Legal Officer
Mr. Jeffrey Ryan Stewart Exec. VP & Chief Commercial Officer
Mr. Scott T. Reents Exec. VP & CFO
Dr. Azita Saleki-Gerhardt Ph.D. Exec. VP of Operations
Dr. Thomas J. Hudson Sr. VP of R&D and Chief Scientific Officer
Ms. Elizabeth Shea VP of Investor Relations
Mr. Perry C. Siatis Exec. VP, Gen. Counsel & Sec.
Mr. Timothy J. Richmond Exec. VP & Chief HR Officer

Exchange: NYSE

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 14.3885
Trailing PE: 21.2173
Price-to-Book MRQ: 18.2288
Price-to-Sales TTM: 4.9887
IPO Date: 2013-01-02
Fiscal Year End: December
Full Time Employees: 50000
Back to stocks